Drugs targeting protein-protein interactions

被引:93
作者
Chene, Patrick
机构
[1] Oncology Research, Novartis Institutes for Biomedical Research, Basel
关键词
drug design; hdm2; p53; protein interfaces; protein-protein interactions;
D O I
10.1002/cmdc.200600004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Most biological processes involve permanent and nonpermanent interactions between different proteins, and many protein complexes play a key role in various human diseases. Therefore, molecules that prevent the formation of these protein complexes could be valuable new therapeutic agents to treat these diseases. Protein interfaces have not evolved to bind low-molecular-weight molecules, as is the case with enzyme catalytic sites. It is therefore difficult to identify small compounds that inhibit protein-protein interactions. However, there is considerable diversity in the structure of protein interfaces, some of which may be more attractive than others for medicinal chemistry. One of the main challenges in drug discovery is to identify these interfaces and to exploit their properties to make marketable drugs. Herein, the properties of protein interfaces are discussed in light of their use as drug targets.
引用
收藏
页码:400 / 411
页数:12
相关论文
共 62 条
  • [41] Diversity of protein-protein interactions
    Nooren, IMA
    Thornton, JM
    [J]. EMBO JOURNAL, 2003, 22 (14) : 3486 - 3492
  • [42] Analysing six types of protein-protein interfaces
    Ofran, Y
    Rost, B
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 325 (02) : 377 - 387
  • [43] ONCOPROTEIN MDM2 CONCEALS THE ACTIVATION DOMAIN OF TUMOR SUPPRESSOR-P53
    OLINER, JD
    PIETENPOL, JA
    THIAGALINGAM, S
    GVURIS, J
    KINZLER, KW
    VOGELSTEIN, B
    [J]. NATURE, 1993, 362 (6423) : 857 - 860
  • [44] THE P53-MDM2 AUTOREGULATORY FEEDBACK LOOP - A PARADIGM FOR THE REGULATION OF GROWTH-CONTROL BY P53
    PICKSLEY, SM
    LANE, DP
    [J]. BIOESSAYS, 1993, 15 (10) : 689 - 690
  • [45] PICKSLEY SM, 1994, ONCOGENE, V9, P2523
  • [46] Polsky D, 2001, CANCER RES, V61, P7642
  • [47] Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
    Roth, J
    Dobbelstein, M
    Freedman, DA
    Shenk, T
    Levine, AJ
    [J]. EMBO JOURNAL, 1998, 17 (02) : 554 - 564
  • [48] Molecular mechanism of the interaction between MDM2 and p53
    Schon, O
    Friedler, A
    Bycroft, M
    Freund, SMV
    Fersht, AR
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2002, 323 (03) : 491 - 501
  • [49] Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
  • [50] Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO